Vietnam Pharmaceuticals: key facts

Last updated 2026-11-11 · 9 sourced answers from KIRA RESEARCH reports and field research. Every figure shows its year and source.

Market size

How big is Vietnam's drug market?

Vietnam's drug market was about USD 8.0 bn in 2025, growing about 7% a year to 2030, according to KIRA's 2026 market report (Fortune BI 2025).

Source: Fortune BI 2025, 2025 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

What share of hospital tender value goes to domestic suppliers in Vietnam?

Domestic suppliers held 26.2% of hospital tender value on a VND 34.7tn 2023 base, according to KIRA's 2026 market report (VSS 2024).

Source: VSS 2024, 2023 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

Key players

How much of Imexpharm in Vietnam does SK Group own?

SK Group holds about 48% of Imexpharm, according to KIRA's 2026 market report (VIR 2024).

Source: VIR 2024, 2024 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

Channels and distribution

What share of Vietnam's drug market is tender-driven ETC?

The tender-driven ETC channel accounts for about 75% of Vietnam's drug market value in 2025, according to KIRA's 2026 market report (Stellapharm 2025).

Source: Stellapharm 2025, 2025 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

How much of Vietnam's drug market value does the pharmacy channel drive?

The pharmacy channel drives 61% of market value and grew 11% in H1 2025, according to KIRA's 2026 market report (VIRAC 2025).

Source: VIRAC 2025, 2025 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

Pricing

How much cheaper are biosimilars than reference biologics in Vietnam?

Biosimilars trade at 50-70% ASP discounts to reference biologics, according to KIRA's 2026 market report (InsightAce 2025).

Source: InsightAce 2025 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

Regulation

What is Decision 1165's domestic target for Vietnam's drug market?

Decision 1165 targets domestic drugs at 70% of market value by 2030, according to KIRA's 2026 market report (Decision 1165 2023).

Source: Decision 1165 2023, 2030 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

How many plants in Vietnam hold EU-GMP certification?

Only 17 plants nationally hold EU-GMP certification, according to KIRA's 2026 market report (InvestVietnam 2025).

Source: InvestVietnam 2025 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

Risks

How dependent is Vietnam on imported APIs?

Local production covers only a fraction of Vietnam's API needs, with import dependency above 80%, according to KIRA's 2026 market report (Kira estimates based on Davipharm + EuroCham 2024).

Source: Kira estimates based on Davipharm + EuroCham 2024, 2024 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

Who's who

pharmaceutical products

47 companies in BizDirect Asia's database. Supplier list · Distributor list · Manufacturer list

Top regions: Ha Noi (18), Ho Chi Minh (13), Dak Lak (1), An Giang (1), Bac Ninh (1)

active pharmaceutical ingredients

8 companies in BizDirect Asia's database. Distributor list · Manufacturer list

Top regions: Ho Chi Minh (4), Khanh Hoa (1)

pharmaceutical excipients

10 companies in BizDirect Asia's database. Distributor list

Top regions: Ho Chi Minh (5), Phu Tho (1), Khanh Hoa (1)

pharmaceutical raw materials

20 companies in BizDirect Asia's database. Supplier list · Distributor list · Manufacturer list · Wholesaler list

Top regions: Ho Chi Minh (8), Ha Noi (7), Phu Tho (1), Hung Yen (1), Hai Phong (1)

Company data: BizDirect Asia (sister company)